Grace Therapeutics reports Q2 loss of $0.9M; FDA accepts NDA for GTx-104 with PDUFA April 23, 2026

Grace Therapeutics, Inc.

2026-Q2 EPS reported -$0.27

Net loss $0.9M ($0.06 loss per share) vs $3.4M ($0.30 loss) in Q2 last year.
FDA accepted NDA for GTx-104 (nimodipine IV) for aSAH; PDUFA target date April 23, 2026.
U.S. patent issued for IV dosing regimen; IP protection extended to 2043.
Cash $16.9M at Sept 30, 2025; ~$20.0M at Oct 31, 2025 after $4.0M warrant exercises.
R&D expenses fell 80% to $0.6M due to completion of Phase 3 STRIVE-ON trial.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.